Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials.
Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M 3rd, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE; NRG Prostate Cancer AI Consortium; Sandler HM, Tran PT, Spratt DE, Pugh S, Feng FY, Mohamad O.
Esteva A, et al.
NPJ Digit Med. 2022 Jun 8;5(1):71. doi: 10.1038/s41746-022-00613-w.
NPJ Digit Med. 2022.
PMID: 35676445
Free PMC article.
This artificial intelligence-based tool improves prognostication over standard tools and allows oncologists to computationally predict the likeliest outcomes of specific patients to determine optimal treatment. ...
This artificial intelligence-based tool improves prognostication over standard tools and allows oncologists to computationally predic …